Chondrogenix, a wholly owned subsidiary of Mogrify Ltd, a Cambridge, UK-based company innovation development of cell therapies, secured funding from SBRI Healthcare, the NHS England funded initiative championed by the AHSN Network.
The amount of the deal was not disclosed.
The company intends to use the funds to develop a source of therapeutic cells for the treatment of osteoarthritis.
The Mogrify Platform (Rackham et al., Nature Genetics, 2016) has been used by Chondrogenix to convert multiple starting cell types to functional chondrocytes capable in vitro of spontaneously forming cartilage, and this funding will support the partnering of this asset to take it through the remaining pre-clinical stages before entering clinical trials.
Following on from a proof-of-concept study, Chondrogenix is using a cocktail of small molecules (identified by the Mogrify Platform) to transdifferentiate several different starting cell types, directly sourced from diseased patients, into functional hyaline chondrocytes to ultimately be used in the clinic to enhance the already approved Autologous Chondrocyte Implantation (ACI) therapy and create additional allogeneic and in vivo reprograming therapies. It will apply for the Phase 2 funding from SBRI Healthcare for £1 million GBP, which will support the progression of the Company’s lead asset into the clinic.